Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: CTLA-4/FasL fusion protein - KAHR Medical

Drug Profile

Research programme: CTLA-4/FasL fusion protein - KAHR Medical

Alternative Names: KAHR-102

Latest Information Update: 11 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator KAHR Medical
  • Class Antineoplastics; Proteins
  • Mechanism of Action Apoptosis stimulants; CD80 antigen inhibitors; CD86 antigen inhibitors; CD95 antigen stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Lymphoma
  • No development reported Autoimmune disorders

Most Recent Events

  • 11 Apr 2018 Preclinical trials in Lymphoma in Israel (unspecified route) (KAHR Medical pipeline, April 2018)
  • 11 Apr 2018 KAHR Medical plans clinical evaluation of KAHR 102 for Lymphoma, in 2019 (KAHR Medical pipeline, April 2018)
  • 09 Dec 2017 Pharmacodynamics and adverse events data from preclinical studies in Cancer presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top